Whole blood lead levels are associated with biomarkers of joint tissue metabolism in African American and white men and women: The Johnston County Osteoarthritis Project by Nelson, Amanda E. et al.
Whole blood lead levels are associated with biomarkers of joint
tissue metabolism in African American and White men and
women: The Johnston County Osteoarthritis Project
Amanda E. Nelsona, Sanjay Chaudharya, Virginia B. Krausb, Fang Fangc, Jiu-Chiuan
Chend, Todd A. Schwartza,e, Xiaoyan A. Shif, Jordan B. Rennera,g, Thomas V. Stablerb,
Charles G. Helmickh, Kathleen Caldwellh, A. Robin Poolei, and Joanne M. Jordana
aThurston Arthritis Research Center, University of North Carolina, 3300 Thurston Bldg, Chapel
Hill, NC, 27599, USA
bDuke University Medical Center, 595 La Salle St., Durham, NC, 27710, USA
cStatWorks, Inc, 79 T.W. Alexander Drive, RTP, NC, 27709, USA
dUniversity of Southern California, Department of Preventative Medicine, Division of
Environmental Health, 1540 Alcazar St., Los Angeles, CA, 90089, USA
eDepartment of Biostatistics, Gillings School of Global Public Health, University of North Carolina,
3106E McGavran-Greenberg Hall, Chapel Hill, NC, 27599, USA
fSAS Institute, Inc, SAS Campus Drive, Cary, NC, 27513, USA
gUniversity of North Carolina, Department of Radiology, 509 Old Infirmary Bldg, Chapel Hill, NC,
27599, USA
hCenters for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA, 30333, USA
iJoint Diseases Laboratory, Shriners Hospital; Department of Surgery, McGill University, 1529
Cedar Ave, Montreal, Quebec, H3G 1A6, Canada
Abstract
Purpose—To examine associations between biomarkers of joint tissue metabolism and whole
blood lead (Pb), separately for men and women in an African American and Caucasian population,
which may reflect an underlying pathology.
Methods—Participants in the Johnston County Osteoarthritis Project Metals Exposure Sub-study
(329 men and 342 women) underwent assessment of whole blood Pb and biochemical biomarkers
of joint tissue metabolism. Urinary cross-linked N telopeptide of type I collagen (uNTX-I) and C-
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telopeptide fragments of type II collagen (uCTX-II), and serum cleavage neoepitope of type II
collagen (C2C), serum type II procollagen synthesis C-propeptide (CPII), and serum hyaluronic
acid (HA) were measured using commercially available kits; the ratio of [C2C:CPII] was
calculated. Serum cartilage oligomeric matrix protein (COMP) was measured by an in-house
assay. Multiple linear regression models were used to examine associations between continuous
blood Pb and biomarker outcomes, adjusted for age, race, current smoking status, and body mass
index. Results are reported as estimated change in biomarker level for a 5-unit change in Pb level.
Results—The median Pb level among men and women was 2.2 and 1.9 µg/dL, respectively.
Correlations were noted between Pb levels and the biomarkers uNTX-I, uCTX-II, and COMP in
women, and between Pb and uCTX-II, COMP, CPII, and the ratio [C2C:CPII] in men. In adjusted
models among women, a 5-unit increase in blood Pb level was associated with a 28% increase in
uCTX-II and a 45% increase in uNTX-I levels (uCTX-II: 1.28 [95%CI: 1.04–1.58], uNTX-I: 1.45
[95%CI:1.21–1.74]). Among men, levels of Pb and COMP showed a borderline positive
association (8% increase in COMP for a 5-unit change in Pb: 1.08 [95% CI: 1.00–1.18])); no other
associations were significant after adjustment.
Conclusions—Based upon known biomarker origins, the novel associations between blood Pb
and biomarkers appear to be primarily reflective of relationships to bone and calcified cartilage
turnover among women and cartilage metabolism among men, suggesting a potential gender-
specific effect of Pb on joint tissue metabolism that may be relevant to osteoarthritis.
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1. Introduction
Approximately 95% of total body lead (Pb) burden in adults is stored in bone (Wittmers, Jr.
et al. 1988), and despite decreased Pb exposure in the United States in recent years (Muntner
et al. 2005;Centers for Disease Control and Prevention (CDC) 2009), people with previous
exposure to this ubiquitous environmental toxicant may have accumulated significant Pb
burden in bone. Bone Pb has a half-life of decades, and contributes as much as 65% to
measured whole blood Pb levels (Barry and Mossman 1970). The stored bone Pb can be
released into blood chronically, especially during times of increased bone turnover (Machida
et al. 2009;Nie et al. 2009), making bone both a potential target tissue for Pb toxicity and a
persistent endogenous source of Pb (Symanski and Hertz-Picciotto 1995;Mushak
1993;Osterloh et al. 1994;Berlin et al. 1995;Nash et al. 2004). Even mild elevations in blood
Pb may have health consequences, including increased mortality, as shown by recent studies
using data from the Third National Health and Nutrition Examination Survey (Schober et al.
2006) and the Study of Osteoporotic Fractures (Khalil et al. 2009).
There exist several biologically plausible ways by which long-term exposure to Pb may
impact bone and other joint structures in humans. For instance, Pb is known to interfere with
dietary calcium uptake and metabolism, conversion of vitamin D to 1, 25-OH vitamin D,
and other regulatory aspects of bone cellular function and matrix and osteocalcin synthesis
(Berlin et al. 1995;Fullmer 1997;Pounds et al. 1991). Pb exposure leads to impaired collagen
synthesis by osteoblasts and impaired resorptive capacity by osteoclasts (Pounds et al.
1991). Aside from its effects on bone, recent data suggest effects of Pb on cartilage and
chondrocytes as well. Zuscik and colleagues reported reversion of articular chondrocytes to
a more primitive phenotype upon Pb exposure, with matrix degradation and mineralization,
decreased TGF-β signaling, and chondrocyte hypertrophy (Zuscik et al. 2006). A related
study revealed impairments in fracture healing in Pb-exposed mice, with associated delays
in endochondral maturation (Carmouche et al. 2005). In a study of bone samples from
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individuals without known bone disease or Pb exposure, Zoeger and colleagues identified
marked differential accumulation of Pb in the cartilage tidemark, the transition between
calcified and non-calcified cartilaginous m atrix (Zoeger et al. 2006), where clefts occur as
osteoarthritis develops. The affinity of Pb for joint tissues, and the role of Pb in cartilage and
bone maturation and repair shown in the above studies, suggest a potential role for Pb in the
osteoarthritis disease process, which affects bone, cartilage, and notably the tidemark area of
cartilaginous matrix.
Associations between blood and bone Pb and bone biomarkers have been identified (Tsaih et
al. 2001;Machida et al. 2009;Dowd et al. 2001), but there have been no studies assessing
potential associations between whole blood Pb levels and biomarkers of joint metabolism.
We examined a panel of serum and urine biomarkers, as quantitative indicators of bone and
cartilage turnover (urinary cross-linked N telopeptide of type I collagen (uNTX-I), urinary
C-telopeptide fragments of type II collagen (uCTX-II), serum cartilage oligomeric matrix
protein (COMP), serum cleavage neoepitope of type II collagen (C2C), serum type II
procollagen synthesis C-propeptide (CPII), the ratio of [C2C:CPII], and hyaluronic acid
(HA)), in relationship to whole blood Pb among participants in the Johnston County
Osteoarthritis Project. We hypothesized that Pb levels may be associated with both skeletal
and other joint tissue metabolism, as reflected by levels of these biomarkers, which may be
of potential relevance to osteoarthritis.
2. Patients and Methods
2.1. Study Population
The Johnston County Osteoarthritis Project is a population-based study in which civilian,
non-institutionalized African American and White individuals, 45 years of age and older,
were recruited from 1991-7 by probability sampling of six townships in Johnston County as
previously described (Jordan et al. 2007). The Metals Exposure Sub-study, including whole
blood Pb assessment, was designed to consist of 1700 consecutive individuals either newly
enrolled in 2003-4, or returning for follow-up in 2006-8. The sample for the current analysis
includes individuals who had complete blood Pb data when the biomarker assays were
performed, consisting of 342 women and 212 men enrolled in 2003-4, and 117 men
returning for follow-up in 2006-8. The characteristics of this subsample were similar to
those of the overall metals sample (n=1635, Table 1). This study has been approved by the
Institutional Review Boards of the Centers for Disease Control and Prevention and the
University of North Carolina.
Demographic and clinical information was obtained by interview, race was self-reported,
and current smoking status was assessed by questionnaire, coded as either a current smoker
or a current nonsmoker. Participants underwent a clinical evaluation, which included
measurement of height (m) without shoes and weight (kg) measured with a balance beam
scale, followed by calculation of body mass index (BMI, in kg/m2). For women, menopausal
status was determined by an affirmative answer to the following question: “Have you
reached menopause or change of life?” For those who were not sure how to answer this
question, post-menopausal status was inferred by the absence of menstrual periods for 2
years in women aged 50 and older, or by the report of surgical removal of both ovaries.
Female participants were also asked if they were currently using, or had ever used hormone
pills, creams, patches, or shots, not including birth control pills. These factors were included
in adjusted analyses due to known effects of race, smoking, and menopausal status on
biomarker and blood Pb levels.
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2.2. Blood Lead (Pb) Assay
Whole blood was collected utilizing certified metal-free blood drawing equipment and vials,
and stored at ~4 degrees (Wang and Peter 1985;Subramanian 1995) until shipment in
batches of 50–100 to the Division of Laboratory Sciences (National Center for
Environmental Health, Centers for Disease Control and Prevention, CDC) for analysis.
Whole blood Pb concentrations were determined at the CDC using the PerkinElmer
Inductively coupled plasma-dynamic reaction cell-mass spectrometer 6100 ELAN series
DRC II, ELAN® DRC II ICP-MS (PerkinElmer SCIEX, Concord, Ontario, Canada)
equipped with a Meinhard nebulizer and cyclonic spray chamber. In this multi-element
analytical technique, blood samples are diluted with ≥ 18 M-ohm.cm water and with diluent
containing 1% v/v tetramethyl-ammonium hydroxide, 0.5% disodium ethylenediamine
tetraacetate, 10% ethyl alcohol, and 0.05% Triton X-100. Gold is added to reduce intrinsic
mercury memory effects. Bismuth was added for the internal standardization of Pb. The
samples were prepared with the following ratio: (Sample: Water: Diluent = 1:1:48). Pb was
quantified based on the ratio of analyte signal to that of the internal standard signal in peak
hopping mode. The calibration was external matrix matched, control samples were assessed
along with participant samples, and accuracy was verified by the analysis of standard
reference material (SRM 955 c) from the National Institute of Standards Technology. For Pb
the limits of detection in µg/dL was based upon the standardization of base blood material
and was 0.25 µg/dL (n=284). The inter-assay precisions (relative standard deviations) for
lead was 3.2% at a level of 2.89 µg/dL.
2.3. Bone and joint tissue biomarker assays
Blood samples for serum biomarker determination were collected, spun and separated on
site, and stored at −86°C. Second morning void urine samples were collected, spun and
stored at −86°C within 8 hours of processing. Details of individual marker properties and
assays are as follows:
Urine NTX-I (cross linked N telopeptide of type I collagen) is a marker of bone
resorption/turnover in health and is increased in osteoporosis (Scariano et al. 1998) and
in osteoarthritis (Bettica et al. 2002). Urine NTX-I was measured using the
commercially available Osteomark NTX Urine kit (Wampole Laboratories, Princeton,
NJ), a competitive-inhibition enzyme linked immunosorbent assay (ELISA) with
reported precision of between 5–19% intra-assay and 3–5% inter-assay variability.
Results are corrected for urine creatinine concentration with final values reported as nM
BCE/mM creatinine.
Urine CTX-II (urinary C-telopeptide fragments of type II collagen) is associated with
both the prevalence and the progression of radiographic knee and hip osteoarthritis,
independent of known clinical risk factors for osteoarthritis (Christgau et al.
2001;Reijman et al. 2004;Kong et al. 2006;Meulenbelt et al. 2006), and is related to
bone, cartilage, and prominently to calcified cartilage turnover (Tomiya et al. 2008;Bay-
Jensen et al. 2008). This marker was measured using the commercially available Urine
Cartilaps competitive ELISA (Nordic Bioscience, Herlev, Denmark), which has a
reported precision of between 4.6–7.8% intra-assay and 6.9–12.2% inter3 assay
variability. Results are corrected for urine creatinine concentration and final values
reported as ng CTX-II /mM creatinine.
Serum COMP (cartilage oligomeric matrix protein), a non-collagenous matrix protein
found in cartilage, meniscus, tendon, and ligament (Garnero et al. 2000;Petersson et al.
1998), is a widely studied and validated cartilage biomarker in relation to osteoarthritis
(Clark et al. 1999;Jordan et al. 2003;Sharif et al. 1995b). COMP was measured using a
previously described sandwich ELISA method utilizing monoclonal antibodies 16F12
Nelson et al. Page 4













and 17C10, with a precision of between 5.8–6.6% intra-assay and 8.7–9.7% inter-assay
variability (Vilim V et al. 2002). Results are reported as ng/ml COMP.
Serum C2C (collagenase-generated cleavage neoepitope of type II collagen) is
indicative of cartilage collagen degradation, and is elevated in animal models of
osteoarthritis (Chu et al. 2002;Matyas et al. 2004). Elevation of urine C2C (but not
serum) is associated with pre-radiographic knee osteoarthritis onset (Cibere et al. 2009);
in this study only serum C2C was measured, using the commercially available Collagen
Type II Cleavage ELISA (Ibex Pharmaceuticals, Montreal, Quebec, Canada). This
competitive ELISA has a reported precision of 9.7% intra-assay (Mazzuca et al. 2006)
and <20% inter-assay variability (Ibex data sheet). Results are reported as ng/ml C2C.
Serum CPII (type II collagen c-propeptide) is cleaved from type II procollagen
following release of synthesized procollagen in cartilage matrix, and is therefore
indicative of type II collagen synthesis (Nelson et al. 1998); CPII was measured using
the commercially available Procollagen II C-Propeptide ELISA (Ibex Pharmaceuticals,
Montreal, Quebec, Canada). This competitive ELISA has a reported precision of 6.4%
intra-assay (Mazzuca et al. 2006) and <25% inter-assay variability (Ibex data sheet).
Results are reported as ng/ml CPII.
Serum [C2C:CPII] ratio was calculated from the values of serum C2C and CPII. This
ratio is indicator of the balance between cartilage collagen degradation and synthesis
which is reflective progression of knee osteoarthritis (Cahue et al. 2007).
Serum HA (hyaluronan), a widely distributed large polysaccharide, is usually regarded
as an indicator of synovial inflammation in arthritis (Wells et al. 1992;Georges et al.
1997;Sharif et al. 1995a), and may be associated with total osteoarthritis burden (Kraus
VB et al. 2009). We and others have reported strong and robust associations between
both serum COMP and serum HA levels and the presence and severity of radiographic
osteoarthritis (Clark et al. 1999;Sharif et al. 1995b). It was measured using the
commercially available Hyaluronic Acid Test kit (Corgenix, Westminster, CO), an
enzyme-linked binding protein assay with a reported precision of between 3.6–4.7%
intra-assay and 5.7–7.0% inter-assay variability. Results are reported in ng/ml HA.
Urine Creatinine was measured using the commercially available Metra Creatinine Assay
kit (Quidel, San Diego, CA), a colorimetric assay based on a modified Jaffe method with a
reported precision of between 1.1–2.1% intra-assay and 2.0–6.9% inter-assay variability.
Results were used to correct the urine measures (uCTX-II and uNTX-I).
2.4. Statistical Analysis
A total of 329 men and 342 women had available data for whole blood Pb and serum and
urine biomarker (uNTX-I, uCTX-II, COMP, C2C, CPII, [C2C:CPII], and HA) analyses.
Due to known gender differences in biomarkers of joint metabolism (Jordan et al.
2003;Kojima et al. 2008;Elliot et al. 2005;Mouritzen al. 2003), previously shown variations
in Pb level by gender, and our a priori hypotheses, all results were stratified by gender.
Natural logarithm transformation was used to produce distributions closer to normality for
the biomarkers in these analyses. Descriptive statistics were calculated for demographic
variables, smoking status, BMI, blood Pb, and the biomarkers. Spearman correlation
coefficients and 95% CIs were computed between Pb and each biomarker. Due to known
effects of race and smoking both Pb and biomarker levels, the differences in mean Pb (ln-
transformed f or t-tests) and biomarkers by race and smoking status were tested by separate
two sample Student’s t-tests.
Separate multiple linear regression models were used to examine the associations between
Pb and the natural log of each of the biomarkers: uNTX-I, uCTX-II, COMP, C2C, CPII,
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[C2C:CPII], and HA. The models were adjusted for variables known to impact blood Pb
and/or biomarker levels: categorical race and smoking status, and continuous age and BMI.
All of these covariates affected the estimates and were included in final models. Among
women only, additional analyses were conducted restricted to only post-menopausal women
and further adjusted for current hormone replacement therapy. The results of these models
are presented as the estimated change in biomarker level for each 5-unit change in
continuous blood Pb level.
A full model for each biomarker included two-way interactions between Pb and each of age,
BMI, race, and smoking, as well as polynomials of Pb up to the cubic power. Backward
selection was conducted to remove one interaction or the highest order polynomial term at a
time until all p < 0.1. A p-value < 0.1 for an interaction term was considered noteworthy for
potential effect modification, and supplemental analyses including the interaction term were
performed as needed.
Sensitivity analyses were performed by inclusion and exclusion of the outlying observations,
which were defined as those with studentized residuals >3 (Kutner M et al. 2004). One high
value and one low value of COMP were excluded from the analysis of COMP among
women, as the results were found to be sensitive to these two outlying values. No other
biomarker analyses were sensitive to outliers (results did not change when the values were




There were 342 women with data for biomarkers and whole blood Pb; of these, one was
missing menopausal status, two were missing HRT use status, 3 were missing serum
samples, and 12 did not have available urine samples. This left 330 women for analyses of
urine biomarkers and 339 women for serum biomarkers. Demographic and clinical
characteristics are shown in Table 1. Participants had a mean age of 62 years, slightly over
one-third of women were African American, 18% were current smokers, and about 1/3 had
radiographic knee osteoarthritis. The mean BMI among these women was about 31 kg/m2.
The vast majority (96%) were post-menopausal, with 18% of those reporting current HRT
usage. The median and range values for whole blood Pb and biomarkers are shown in Table
2.
The median Pb level was 1.9 µg/dL (range from 0.5–25.4 µg/dL). The mean Pb level (ln-
transformed for t-tests) was noted to be higher among African American compared to
Caucasian women, as were mean levels of ln uCTX-II, ln COMP, and ln C2C. Unadjusted
analyses showed significant correlations between Pb and uNTX-I, uCTX-II, and COMP, but
not with any of the other biomarkers (Table 3).
After adjustment for age, race, smoking status, and BMI, we identified associations between
Pb and the levels of urine biomarkers uNTX-I and uCTX-II, biomarkers primarily reflective
of turnover of mineralized tissues. A 5-unit increase in blood Pb level was associated with a
45% increase in uNTX-I and a 28% increase in uCTX-II levels (Table 4). These positive
associations were unchanged before and after adjustment, and the results were stable when
limited to postmenopausal women and further adjusted for HRT use (data not shown).
Significant interactions between age and Pb were identified for C2C among women (p
interaction 0.07), indicating that age affects the Pb effect for this biomarker. For
representative ages 55, 65, and 75, the expected fold changes in C2C were 1.08, 1.00, and
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0.91 for each 5-fold change in Pb, respectively (Table 4). There were no significant
associations between Pb and COMP, HA, CPII, or the ratio [C2C:CPII], among the entire
sample of women (Table 4), or in analyses limited to post-menopausal women or further
adjusted for HRT use (p>0.1 for all, data not shown).
3.2. Men
The sample consisted of 329 men, with demographic and clinical characteristics as shown in
Table 1. The mean age among the men was 65 years, with a mean BMI of 30 kg/m2. Of this
group, 37% were African American, 23% were current smokers, and nearly 40% had
radiographic knee osteoarthritis. The median and range values for whole blood Pb and
biomarkers are shown in Table 2.
The median Pb level was 2.2 µg/dL (range from 0.5–25.1 µg/dL). The mean Pb level (ln-
transformed for t-tests) was noted to be higher among African American compared to
Caucasian men, and among current smokers compared to non-smokers. Mean levels of ln
C2C were higher among African American compared to Caucasian men, while ln uNTX-I
was higher in Caucasian men; other markers did not differ by race. Pb levels were
significantly positively correlated with uCTX-II, COMP, and the ratio [C2C:CPII], and
negatively correlated with CPII levels, but not correlated with uNTX-I, C2C, or HA (Table
3). There were no race or age interactions identified for Pb and any of the biomarker
outcomes among men.
After adjustment for age, race, smoking status, and BMI, the only significant association
was a borderline one between Pb and COMP, such that for a 5-unit increase in blood Pb,
there was an 8% increase in COMP level (1.08 [95%CI: 1.00–1.18]). There were no
significant associations among men between Pb and uNTX-I, uCTX-II, C2C, CPII,
[C2C:CPII], or HA.
4. Discussion
In summary, in unadjusted analyses, significant correlations were seen between Pb level and
levels of uNTX-I, uCTX-II, and COMP among women and levels of uCTX-II, COMP, CPII,
and [C2C:CPII] among men. After adjustment, among women, we identified statistically
significant positive associations between whole blood Pb level and urine NTX-I and CTX-II,
markers of bone and calcified cartilage turnover, respectively. Among men, there was a
statistically significant positive association between blood Pb and COMP after adjustment.
Blood Pb was not significantly associated with serum C2C, CPII, the ratio [C2C:CPII], or
HA, in adjusted analyses in men or women.
The positive association among women between blood Pb and uCTX-II level in this analysis
signifies a potential association between Pb exposure and joint tissue metabolism, although
we cannot determine the direction of this effect from the present cross-sectional study. It is
unclear whether this finding reflects a direct effect of Pb on cartilage, or an indirect effect
mediated by adverse effects of Pb on bone. Urine CTX-II is a quantitative marker of
radiographic osteoarthritis (Meulenbelt et al. 2006;Reijman et al. 2004), and may be a
relatively specific biomarker of calcified cartilage turnover at the junction of cartilage and
subchondral bone (Tomiya et al. 2008;Bay-Jensen et al. 2008). Given the reported
propensity for accumulation of Pb at the tidemark, the area of transition between calcified
and more metabolically active non-calcified cartilage (Zoeger et al. 2006), and the report
that CTX-II is primarily derived from sites at or near the junction of cartilage and
subchondral bone (Bay-Jensen et al. 2008), uCTX-II may be a specific biomarker for the
joint tissue most affected by Pb toxicity. We have identified significant associations between
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blood Pb and uCTX-II among women in our cohort; confirmation of this finding in other
populations will provide a better understanding of its potential implications.
The strongest association between Pb and a biomarker among women was for uNTX-I, a
marker of bone turnover in osteoporosis (Scariano et al. 1998) and in osteoarthritis (Bettica
et al. 2002). Consistent with prior studies of markers of bone turnover and blood Pb levels
(Potula et al. 2005;Machida et al. 2009), uNTX-I was highly associated with blood Pb level
in the current analysis. Despite known variations in uNTX-I by menopausal and hormone
replacement status, there was no difference after adjustment for these factors in the current
analysis, potentially due to small numbers of premenopausal women and of women on
hormone replacement therapy. The observed association i n the current analysis between
elevated levels of uNTX-I and higher levels of blood Pb is likely related to increased release
of Pb into blood from bone in this population of primarily post-menopausal women in a high
bone turnover state, consistent with prior reports (Machida et al. 2009). Although we did not
identify an association between uNTX-I and blood Pb in men, in a study of elderly men
participating in the VA Normative aging study, there was evidence of increased blood Pb
with increasing uNTX-I levels, although this was not the focus of the study (Nie et al. 2009).
The men in that study were older (mean age 69 years) with a higher median blood Pb level
(5µg/dL) compared to the current analysis, which may at least partly explain this difference.
In contrast to the women, the only significant association among the men was between blood
Pb and serum COMP. Serum COMP, one of the most studied and validated cartilage
biomarkers in relation to osteoarthritis (Clark et al. 1999;Jordan et al. 2003;Sharif et al.
1995b), is not specific to cartilage, as it is also found in meniscus, tendon, and ligament
(Garnero et al. 2000;Petersson et al. 1998). Among women, there was no significant
association between serum COMP and blood Pb after adjustment, despite a significant
Spearman correlation coefficient. Prior studies have shown gender differences in COMP
(Jordan et al. 2003;Sharif et al. 1995b;Kumm et al. 2006), with generally higher levels
among men.
No significant associations were identified between Pb and serum CPII (marker of collagen
synthesis), serum C2C (marker of cartilage degradation), or their ratio [C2C:CPII] in
adjusted analyses, despite significant correlations between Pb level and CPII and
[C2C:CPII] among men. There was a significant interaction between age and C2C among
women, but the association between Pb and serum C2C was not significant in either age
group. A lack of association between radiographic osteoarthritis and serum C2C has been
reported (Mazzuca et al. 2006;Cahue et al. 2007;Cibere et al. 2009), and may represent a
lack of a detectable relationship between the effects of Pb on uncalcified cartilage
degradation, as reflected by serum C2C. Therefore, urine C2C is recommended for future
studies, as unlike serum C2C this biomarker has revealed alterations in cartilage collagen
degradation with the onset of knee osteoarthritis (Cibere et al. 2009). The lack of association
between Pb and the ratio [C2C:CPII], despite evidence in the literature that such marker
ratios may provide additional information beyond that from individual markers in isolation
(Cahue et al. 2007;Cibere et al. 2009), may be in part due to adjustment of the models for
race (associated with C2C) and smoking (associated with CPII).
The lack of association between blood Pb and serum HA, often considered a marker of
synovial inflammation (Wells et al. 1992;Sharif et al. 1995a), among men or women, is not
supportive of a Pb effect on synovium. Studies have shown an effect of Pb on cultured
synovial cells, including decreased proliferation and protein synthesis, but only in an in vitro
experiment using 10-fold higher concentrations of Pb, so it is unclear how those findings
relate to Pb level and serum HA as analyzed in the current study (Goldberg et al. 1983).
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There are some limitations to the current study. Whole blood Pb measurements were used as
a biomarker for Pb exposure. Specialized x-ray fluorescence techniques to assess bone Pb
are considered the “gold standard” for measurement of Pb storage in bone, but this
procedure is expensive and not widely available (Barbosa et al. 2005;Sakai 2000). Since
blood Pb levels reflect recent exposure as well as mobilization of Pb from bone (Barbosa et
al. 2005;Nie et al. 2009), and blood Pb has been associated with all-cause mortality,
cardiovascular disease, and renal disease (Staessen et al. 1992;Jain et al. 2007;Martin et al.
2006;Schober et al. 2006;Weisskopf et al. 2009;Khalil et al. 2009), this measure of Pb was
used as a readily available and economical alternative biomarker for Pb exposure (Barbosa
et al. 2005;Sakai 2000). The current study is also limited due to its cross-sectional design,
although the potential for future longitudinal studies of Pb in this population exist. Bone
density measurements have been collected as part of the parent study but were not
interpreted or analyzed at the time of this analysis. The strengths of this study include a
population-based, biracial sample and the inclusion of multiple biomarkers representing
turnover of different joint tissues.
5. Conclusions
In conclusion, this is the first study evaluating potential effects of low levels of whole blood
Pb on multiple biomarkers of joint tissue metabolism. Whole blood Pb levels reflect
systemic Pb from both current exposure and bone turnover causing release of stored Pb. Our
results suggest that systemic Pb is associated with bone turnover (uNTX-I), as well as
mineralized (uCTX-II) among women, and non-mineralized (COMP) cartilage turnover
among men, but as this is a cross-sectional analysis, we cannot determine whether cartilage
turnover is an indicator, or consequence, of Pb release. The association between blood Pb
level and cartilage-associated biomarkers, along with our recent cross-sectional analysis
showing associations between blood Pb and radiographic knee osteoarthritis and knee
symptoms (Nelson et al. 2011), suggests the possibility that Pb may play a role in the
pathophysiology of osteoarthritis. Longitudinal studies including assessments of
radiographic and symptomatic osteoarthritis, in conjunction with both blood and bone Pb,
would be valuable to further evaluate the potential effects of Pb on joint symptoms, onset
and progression of this highly prevalent and often debilitating disease.
Research Highlights
• We assessed whole blood lead in conjunction with osteoarthritis biomarkers.
• In women, blood lead is associated with urine biomarkers of calcified cartilage
and bone turnover,
• And in men with cartilage oligomeric matrix protein, a serum marker of joint
tissue metabolism,
• Suggestive of a gender-specific effect of lead on joint tissues of potential
relevance in osteoarthritis.
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Table 1
Characteristics of the biomarkers and metals exposure sub-study of the Johnston County Osteoarthritis Project
Clinical Characteristics Women (n=342) Men (n=329) Overall (n=1635)*
Mean (SD) or % Mean (SD) or % Mean (SD) or %
Mean age (SD, years) 62.4 (9.4) 64.5 (10.8) 65.3 (11.0)
Mean BMI (SD, in kg/m2) 30.8 (7.0) 29.8 (5.4) 31.2 (7.1)
African American (%) 35.1 37.4 35.6
Current smoker (%) 17.7 23.1 16.5
Knee Osteoarthritis (%)† 32.8 38.9 40.3
SD: standard deviation; BMI: Body Mass Index
*
Overall numbers are for the entire sample with blood Pb and knee radiographs, including the biomarker subset.
†
Knee osteoarthritis defined as a Kellgren-Lawrence grade ≥2 at either knee or knee replacement due to osteoarthritis.













Nelson et al. Page 15
Table 2
Whole blood lead and serum or urine biomarker levels in the biomarkers and metals exposure sub-study of the
Johnston County Osteoarthritis Project, by gender
Concentration
Women (n=342)a Men (n=329)
Median Range Median Range
Whole blood Lead (µg/dL) 1.9 0.5–25.4 2.2 0.5–25.1
uNTX-I (nmol BCE/mmol creatinine) 86.5 12.8–996.4 39.5 5.9–4214.7
uCTX-II (ng/mmol creatinine) 185.2 8.09–1396.6 234.5 47.5–2705.0
COMP (ng/mL) 1597.0 472.9–4429.6 1329.0 339.3–7279.0
C2C (ng/mL) 167.7 72.0–1060.2 177.1 54.0–935.6
CP II (ng/mL) 857.6 228.0–2991.3 937.8 319.9–2352.1
[C2C:CPII] ratio 0.20 0.05–0.76 0.19 0.05–0.92
HA (ng/mL) 12.5 0.1–391.3 40.8 0.6–707.8
a
3 missing serum and 12 missing urine data
uCTX-II- Urine C-telopeptide fragments of type II collagen, COMP-Cartilage Oligomeric matrix protein, CPII: type II collagen carboxy-
propeptide, C2C: cleavage neoepitope of type II collagen, HA- Hyaluronic Acid, uNTX-I- urine N-telopeptide of type I collagen, BCE: bone
collagen equivalent
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Table 3
Spearman correlation coefficients (unadjusted) between individual biomarkers and blood Pb in the biomarkers







uNTX-I 0.220 0.107, 0.314 0.005 −0.103, 0.113
uCTX-II 0.202 0.093, 0.300 0.113 0.004, 0.218
COMP 0.138 0.016, 0.226 0.231 0.125, 0.330
C2C −0.013 −0.120, 0.093 0.038 −0.070, 0.146
CPII 0.028 −0.079, 0.134 −0.110 −0.215, −0.002
[C2C:CPII] −0.026 −0.132, 0.081 0.144 0.037, 0.248
HA 0.067 −0.039, 0.172 −0.003 −0.110, 0.106
uNTX-I- urine N-telopeptide of type I collagen, uCTX-II- Urine C-telopeptide fragments of type II collagen, COMP-Cartilage oligomeric matrix
protein, HA- Hyaluronic Acid, C2C: cleavage neoepitope of type II collagen, CPII: type II collagen carboxy-propeptide
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